News & Media

2021 saw a significant improvement in Norbrook’s financial performance, particularly in the UK and US markets.

Friday 17 December 2021   
2021 saw a significant improvement in Norbrook’s financial performance

2021 saw a significant improvement in Norbrook’s financial performance, particularly in the UK and US markets.

Norbrook Holdings Ltd today announced its results for the year to 30th July 2021 which show Revenue of £231million, up 9% year-on-year (CER:12%), generating Operating Profit of £28.4 million.

A continuous program of significant capital investment has provided the platform for strong growth in a buoyant veterinary pharmaceutical market.

The Company has continued to invest in the future of the business, with capital investment of £12 million in 2021, representing 5% of Revenue, bringing the total invested in the last six years to £75 million.

 The Company’s output and delivery performance improved as progress was made overcoming manufacturing supply chain challenges and difficult operational conditions due to theCovid-19 pandemic. Improved delivery performance saw the Company’s Operating Profit increase to £28.4 million, compared to the disappointing 2020 performance of £4.4million.


Liam Nagle, Chairman & Chief Executive Officer, Norbrook said, “Having returned to normalised levels of supply, we drove to regain lost market share, working with our customers with whom we have strong, long term, close relationships.”

“Our Teams have tirelessly supported the business recovery over the last year, while adapting to working within Covid-19 protocols which were necessitated to ensure a safe working environment. We are deeply grateful for our employees’ continued support.”

“As we realise the benefits from our Capital Investments, with £75 million invested over the past 6 years in manufacturing facilities, scientific laboratories, and with our strong pipeline of new product launches, Norbrook is well positioned for the future”.